ALK and non-small cell lung carcinoma: Different from the previous sequential administration, a Japanese team administered ALK-TKI (Crizotinib/Alectinib/Ceritinib) and WBRT simultaneously to patients with brain metastasis of ALK rearranged NSCLC for the first time, and found that this method may cause serious ototoxicity (43).